Real-world treatment patterns and clinical outcomes in patients with emerging estrogen receptor 1 (ESR1)-mutated ER+ metastatic breast cancer in the U.S., 2018-2024.

Jane L Meisel¹, Clara Chen², Ayush Kris³, Meng Ru², Timothy Pham², James Roose⁴

¹Department of Hematology and Medical Oncology, Emory Winship Cancer Institute, Emory University, Atlanta, GA, USA.

²AstraZeneca, Gaithersburg, MD, USA.

³Flatiron Health, New York, NY, USA.

⁴Flatiron Health, New York, NY, USA. james.roose@flatiron.com.

PubMed DOI

Abstract

PURPOSE: Clinical studies have highlighted the potential utility of monitoring for Estrogen receptor alpha 1 (ESR1) mutation (m) (ESR1m) emergence during first-line therapy (1L) for metastatic breast cancer (mBC). However, less is known about the real-world practice for patients with emergent ESR1m before progression and their outcomes. This study aimed to characterize real-world treatment pattern…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.